Reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
At about T+5 minutes was SECO (Sustainer Engine Cutoff) and Faith 7 entered orbit at 17,547 mph (7,844 m/s). After the spacecraft separated and turned around to orbit attitude, Cooper watched the spent Atlas lag behind and tumble for about eight minutes. Over Zanzibar on the first orbit, he learned that the orbital parameters were good enough for at least 20 orbits. As the spacecraft passed over Guaymas, Mexico still on the first orbit, capsule communicator Gus Grissom told Cooper the ground computers said he was "go for seven orbits." Atlas performance was overall excellent. The upgraded propulsion system worked well, with slightly above nominal booster engine thrust. Measurable propellant slosh occurred from T+55 to T+120 seconds, caused by slightly lower than nominal autopilot gains. The flight trajectory was slightly more lofted than nominal due to the DC voltage in the booster electrical system being about 0.7 volts above normal, but this was counteracted by the higher than nominal booster engine performance. BECO took place at T+132 seconds, escape tower jettison at T+141 seconds, and SECO at T+303 seconds.
== Attempted murder trials == In 1982, von Bülow was arrested and tried for the attempted murders of Sunny on two occasions in two consecutive years. The main medical and scientific evidence against him was that Sunny had low blood sugar, common in many conditions, but a blood test showed a high insulin level. The test was not repeated. A needle was used as evidence against von Bülow in court, with the prosecution alleging that he had used it and a vial of insulin to try to kill his wife. His mistress of two years, the soap opera actress Alexandra Isles, testified "He said that they had been having a long argument, talk, about divorce that had gone on late into the night. She had drunk a great deal of eggnog. And then he said, 'I saw her take the Seconal.' And then he said that the next day when she was unconscious that he watched her knowing that she was in a bad way, all day, and watched her and watched her. And finally, when she was at the point of dying, he said that he couldn't go through with it and he called (the doctor) and saved her life." The discovery of these items became the focal point of von Bülow's appeal. At the trial in Newport, Rhode Island, von Bülow was found guilty and sentenced to 30 years in prison; he appealed, hiring Harvard Law School professor Alan Dershowitz to represent him. Dershowitz served as a consultant to the defence team led by Thomas Puccio, a former federal prosecutor.
Dustin Andrew Fletcher (born 7 May 1975) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is widely acknowledged as one of the finest defenders in the history of the league, and one of only six players in the history of the VFL/AFL competition to play 400 games. Fletcher is a member of the Australian Football Hall of Fame, and a Legend in the Essendon Hall of Fame.
Sources: en.wikipedia.org
Between 2010 and 2020, reports of overdoses were higher in Australasia, Europe and North America than in Asia, Africa, and South or Central America. It is easily absorbed through intact skin, and vapors are absorbed through the respiratory tract.
18 December: The Ministry of Education cancels Gloriavale Christian School's registration as a private school effective 23 January next year, citing insufficient evidence that the school was complying with registration criteria. Wellington High Court Justice Jason McHerron orders Corrections Department chief executive Jeremy Lightfoot to comply with a legal requirement entitling prisoners to at least one hour of exercise daily. The Waihi North extension of OceanaGold's Waihi mine becomes the first mining project to gain approval under the Fast-track Approvals Act 2024's regime. The Whangarei District Council votes unanimously to reject plans for fast-tracked sand mining at Bream Bay. 19 December: Esarona David Lologa is sentence to life imprisonment with a minimum term of 22 years for murdering five people and causing the Loafers Lodge fire in 2023. High Court Justice David Gendall rules that Justice Minister Paul Goldsmith unlawfully appointed Human Rights Commissioner Stephen Rainbow and Race Relations Commissioner Melissa Derby. 20 December — Members of the Brian Tamaki–aligned "True Patriots of NZ" attempt to block a Sikh rally in Auckland. Police intervene to keep the two groups apart. 22 December — India and New Zealand confirm plans to sign a free trade agreement in 2026. 23 December - A scrub fire destroys multiple buildings and forces the evacuation of several residents between Fernhill, Hawke's Bay and the Ngaruroro River bridge.
== Computing, Internet and information technology == Files-11 (On-Disk Structure), a DEC filesystem Office of Digital Strategy, Executive Branch of the White House OpenDocument Spreadsheet file format Online dating service Operational data store, an intermediate data warehouse for databases OpenDNSSEC, a security extension of DNS Protocol Optical data storage a technology for storing information
Sources: en.wikipedia.org
==== UN Single Convention on Narcotic Drugs ==== On 8 March 2016 at its 59th Session, the Commission on Narcotic Drugs (CND) added Phenazepam to relevant schedules of the Convention on Psychtropic Substances of 1971.
==== Solvent casting and particulate leaching ==== Solvent casting and particulate leaching (SCPL) allows for the preparation of structures with regular porosity, but with limited thickness. First, the polymer is dissolved into a suitable organic solvent (e.g. polylactic acid could be dissolved into dichloromethane), then the solution is cast into a mold filled with porogen particles. Such porogen can be an inorganic salt like sodium chloride, crystals of saccharose, and gelatin or paraffin spheres. The size of the porogen particles will affect the size of the scaffold pores, while the polymer to porogen ratio is directly correlated to the amount of porosity of the final structure. After the polymer solution has been cast the solvent is allowed to fully evaporate, then the composite structure in the mold is immersed in a bath of a liquid suitable for dissolving the porogen: water in the case of sodium chloride, saccharose and gelatin or an aliphatic solvent like hexane for use with paraffin. Once the porogen has been fully dissolved, a porous structure is obtained. Other than the small thickness range that can be obtained, another drawback of SCPL lies in its use of organic solvents which must be fully removed to avoid any possible damage to the cells seeded on the scaffold.
In recent years, the use of freeze-dried starter culture has become common due to stability of the fermentation result, because the species of microbes are selected in laboratory conditions, as well as easy transportation. During fermentation, changes in the composition of ingredients occur. Lactose, the sugar present in milk, is broken down mostly to lactic acid by the lactic acid bacteria, which results in acidification. Propionibacteria further break down some of the lactic acid into propionic acid (these bacteria also carry out the same fermentation in Swiss cheese). Other substances that contribute to the flavor of kefir are pyruvic acid, acetic acid, diacetyl and acetoin (both of which contribute a "buttery" flavor), citric acid, acetaldehyde, and amino acids resulting from protein breakdown.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.